Cahill Represented Envigo in Acquirement by Inotiv
Cahill represented Envigo RMS Holding Corp. (“Envigo”), a leading provider of research models and services, in connection with its acquisition by Inotiv, Inc. (“Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. The combined company will enable drug developers to access products and services for the entirety of discovery and nonclinical development within one organization. The transaction consisted of $271 million of cash, including adjustments for net working capital and cash balances as provided in the merger agreement of approximately $13.0 million and $48.0 million, respectively, and 9,036,538 Inotiv common shares. The common shares included in the merger include 790,620 shares issuable upon the exercise of certain Envigo stock options that were assumed by the Company in the transaction.
The Cahill team representing Envigo was led by corporate partners Kimberly C. Petillo-Décossard, Jonathan A. Schaffzin and Ross E. Sturman, associates Joseph F. Rosati, Tina M. Davis, Tricia B. Reilly and Elizabeth Sweeny, attorney Sarah Klein-Cloud and counsel Dan Anderson; antitrust partner Elai Katz, counsel Lauren Rackow and associate Emily Lentz; environmental associates Peter J. Gioello and Lynn R. Schmidt; executive compensation and benefits counsel Mark J. Gelman; intellectual property counsel Alexander M. Kim and associate Kenneth Ritz; regulatory associate Peter T. Mazzone; and tax partner Craig M. Horowitz and associate Samir Kurani.